In this study, we demonstrate that dapagliflozin mitigates the diabetes-increased CYP4A protein expression and 20-HETE production, which coincided with a decrease in ROS production and NADPH oxidase activity (Figure 2A–D). The gene discussed is FMO5; the disease is diabetes mellitus.